Clinical study results

ERLEADA + ADT helped certain patients live without metastasis 2 years longer compared to placebo + ADT

 

In a clinical trial, ERLEADA + ADT* delayed the spread of cancer to other parts of the body (metastasis) or death by 2 years (24.3 months) compared to placebo + ADT.

MEDIAN MONTHS: Median number of months living without metastasis.

 

*ADT includes medical or surgical treatment that lowers testosterone.

Pronounced "pluh-see-bow": a pill that looks like "real" medicine but contains nothing to affect health.

Median means that for 50% of the patients, living without metastasis was longer than 40.5 months, and for 50% of the patients, it was shorter than 40.5 months.

ERLEADA + ADT was compared to placebo + ADT in a clinical trial of more than 1200 men with non-metastatic castration-resistant prostate cancer (nmCRPC).

One group of men received ERLEADA (240 mg once daily) with ADT (had surgical treatment or were receiving treatment that lowers testosterone). The other group of men received a placebo with ADT.

The clinical study also evaluated these additional measures:

Time to Metastasis

Length of time from when patients began study to when prostate cancer had spread to other parts of the body (based on imaging).

MEDIAN MONTHS

40.5
WITH
ERLEADA
+ ADT

VS

16.6
WITH
PLACEBO
+ ADT

Progression-Free Survival

Length of time patients lived without their prostate cancer spreading to local or distant parts of the body or death.

40.5
WITH
ERLEADA
+ ADT

VS

14.7
WITH
PLACEBO
+ ADT

Overall Survival

Length of time patients lived after starting treatment as part of the study.

This study is ongoing and continues to evaluate overall survival.

Resources and Information

Doctor Discussion Guide

Start a conversation with your doctor.

Download the Guide

What is Metastasis?

Learn More

Talking to Your Doctor

Learn More